Shares of Nasus Pharma jumped 8.4% to $3.69 Monday morning after the company announced the FDA cleared its application to begin a pivotal clinical trial of an intranasal epinephrine powder designed to replace the needle-based EpiPen for severe allergic emergencies. The move came even as broader U.S. markets traded lower, signaling a clear company-specific catalyst.
A Nasal Spray That Beat the EpiPen on Speed In its Phase 2 study, Nasus's drug hit the critical blood-level threshold for epinephrine in a median of 1.69 minutes, compared with 3.47 minutes for the EpiPen — nearly twice as fast. The newly cleared trial will evaluate the drug as a needle-free alternative to EpiPen, comparing self-administration by patients to administration by a healthcare professional. For investors, Phase 2 speed advantages mean nothing unless they hold up in a larger, registration-quality study. Nasus plans to start that pivotal study in Q4 2026 and expects topline data in Q1 2027. That timeline creates a binary event — the stock will likely swing sharply when results land.
A Tiny Valuation Chasing a Huge Market Nasus trades at roughly $62 million in market capitalization.
The epinephrine autoinjector market alone is worth an estimated $3.72 billion in 2026 and is growing at a 7.84% annual clip toward $5.43 billion by 2031.
By comparison, ARS Pharmaceuticals, which already sells an approved nasal-spray epinephrine product, trades at roughly $934 million — generating over $30 million per quarter in revenue. The gap illustrates what successful commercialization could mean for Nasus — but also how much execution risk the market is pricing in today.
The Competition and Cash Question Nasus is competing against deeply entrenched players like Viatris (maker of EpiPen) and other emerging intranasal competitors who may have larger marketing budgets.
The company says it is well-funded through mid-2027 , which should cover the pivotal trial. But if the study succeeds, commercialization would demand far more capital — likely meaning fresh fundraising that could dilute existing shareholders.
What the Analyst Street Thinks Citizens has an Outperform rating on the stock with an $18 price target — roughly five times today's price. That bullish view reflects a best-case scenario. The stock remains a classic small-cap biotech bet: enormous upside if the science works, steep downside if it doesn't. The Q1 2027 data readout will be the next make-or-break moment.